Colon Cancer Study of Fecal Samples in Shanghai, China
- Early detection of colon cancer can improve the chances of successful treatment for most people. This approach is especially important if blood is detected in the stool. However, much better stool sample tests are needed to find this cancer early. To improve the tests, researchers want to collect samples from people who are already being screened for colon cancer. This study will collect information and samples from older adults in Shanghai, China. These adults will be participating in screening tests for colon cancer.
- To collect samples and medical information for colon cancer screening from older adults in Shanghai, China.
- Adults between 50 and 74 years of age who are being screened for colon cancer.
- Participants will be recruited from two community health centers in Shanghai, China.
- Participants will provide information on their medical history and factors related to colon cancer. They will respond to questions on use of medications, diet choices (such as eating red meat), bowel habits, and other factors.
- Participants will collect samples for study. These samples will be collected within 3 days of the screening visit. Particpants will provide a urine sample and four stool samples. They will also use cotton swabs to collect samples from just inside the anus. The samples will be returned to the study doctors for research tests that may indicate who has colon cancer.
- Treatment will not be provided as part of this study.
|Study Design:||Time Perspective: Cross-Sectional|
|Official Title:||Pilot Study of the Fecal Microbiome in the Shanghai Population|
- Participation rate, data quality [ Time Frame: 1 year ] [ Designated as safety issue: No ]
|Study Start Date:||January 2013|
|Study Completion Date:||September 2016|
|Primary Completion Date:||December 2015 (Final data collection date for primary outcome measure)|
Please refer to this study by its ClinicalTrials.gov identifier: NCT01778595
|Shanghai Center for Disease Control and Prevention|
|Principal Investigator:||James J Goedert, M.D.||National Cancer Institute (NCI)|